Cancer of Unknown or Uncertain Primary (CUP) cases constitute 12%-15% of all newly diagnosed cancers per year in the United States.1 These cases can represent a clinical dilemma, because without knowing the primary origin, it can be difficult to select the optimal therapy for patients. RosettaGX Cancer Origin is designed to help provide a diagnosis for such cases. It utilizes proven, proprietary microRNA technology, along with a custom microarray platform to deliver highly accurate results.
RosettaGX Cancer Origin also provides easy reflexing options to other solid tumor assays. With CORE (Cancer Origin REflex), we partner with physicians to help them identify their patient’s tumor of origin and uncover the best treatment path by reflexing to the most appropriate solid tumor assay in our portfolio. This allows physicians to more efficiently get all the information needed to properly diagnose and decide on a treatment plan for their patients who need the best answers and care possible, as quickly as possible.